Attenuation of Allergen-, IL-13-, and TGF-α-induced Lung Fibrosis after the Treatment of rIL-15 in Mice
Endogenous IL-15 deficiency promotes lung fibrosis; therefore, we examined the effect of induced IL-15 in restricting the progression of lung fibrosis. Our objective in this work was to establish a novel therapeutic molecule for pulmonary fibrosis. Western blot, qPCR, and ELISA were performed on the lung tissues of IL-15-deficient mice, and recombinant IL-15 (rIL-15)-treated CC10-IL-13 and CC10-TGF-α mice, and allergen-challenged CC10-IL-15 mice were examined to establish the antifibrotic effect of IL-15 in lung fibrosis. We show that endogenous IL-15 deficiency induces baseline profibrotic cytokine and collagen accumulation in the lung, and pharmacological delivery of rIL-15 downregulates Aspergillus antigen-induced lung collagen, the profibrotic cytokines IL-13 and TGF-β1, and α-SMA+ and FSP1+ cells in mice. To confirm that overexpression of IL-15 diminishes pulmonary fibrosis, we generated CC10-rtTA-tetO7-IL-15 transgenic mice and challenged them with Aspergillus antigen. Aspergillus antigen-challenged, doxycycline (DOX)-treated CC10-IL-15 transgenic mice exhibited decreased collagen accumulation, profibrotic cytokine (IL-13 and TGF-β1) expression, and α-SMA+ and FSP1+ cells compared with IL-15-overexpressing mice not treated with DOX. Additionally, to establish that the antifibrotic effect of IL-15 is not limited to allergen-induced fibrosis, we showed that rIL-15 or IL-15 agonist treatment restricted pulmonary fibrosis even in CC10-IL-13 and CC10-TGF-α mice. Mechanistically, we show that T-helper cell type 17 suppressor IL-15-responsive RORγ+ T regulatory cells are induced in DOX-treated, allergen-challenged IL-15-overexpressing mice, which may be a novel pathway for restricting progression of pulmonary fibrosis. Taken together, our data establishes antifibrotic activity of IL-15 that might be a novel therapeutic molecule to combat the development of pulmonary fibrosis.
Errataetall: |
ErratumIn: Am J Respir Cell Mol Biol. 2021 Aug;65(2):229-230. - PMID 34328408 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
---|---|
Enthalten in: |
American journal of respiratory cell and molecular biology - 61(2019), 1 vom: 01. Juli, Seite 97-109 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Upparahalli Venkateshaiah, Sathisha [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 17.02.2020 Date Revised 07.09.2021 published: Print ErratumIn: Am J Respir Cell Mol Biol. 2021 Aug;65(2):229-230. - PMID 34328408 Citation Status MEDLINE |
---|
doi: |
10.1165/rcmb.2018-0254OC |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM29329822X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM29329822X | ||
003 | DE-627 | ||
005 | 20231225075019.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1165/rcmb.2018-0254OC |2 doi | |
028 | 5 | 2 | |a pubmed24n0977.xml |
035 | |a (DE-627)NLM29329822X | ||
035 | |a (NLM)30702923 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Upparahalli Venkateshaiah, Sathisha |e verfasserin |4 aut | |
245 | 1 | 0 | |a Attenuation of Allergen-, IL-13-, and TGF-α-induced Lung Fibrosis after the Treatment of rIL-15 in Mice |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 17.02.2020 | ||
500 | |a Date Revised 07.09.2021 | ||
500 | |a published: Print | ||
500 | |a ErratumIn: Am J Respir Cell Mol Biol. 2021 Aug;65(2):229-230. - PMID 34328408 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Endogenous IL-15 deficiency promotes lung fibrosis; therefore, we examined the effect of induced IL-15 in restricting the progression of lung fibrosis. Our objective in this work was to establish a novel therapeutic molecule for pulmonary fibrosis. Western blot, qPCR, and ELISA were performed on the lung tissues of IL-15-deficient mice, and recombinant IL-15 (rIL-15)-treated CC10-IL-13 and CC10-TGF-α mice, and allergen-challenged CC10-IL-15 mice were examined to establish the antifibrotic effect of IL-15 in lung fibrosis. We show that endogenous IL-15 deficiency induces baseline profibrotic cytokine and collagen accumulation in the lung, and pharmacological delivery of rIL-15 downregulates Aspergillus antigen-induced lung collagen, the profibrotic cytokines IL-13 and TGF-β1, and α-SMA+ and FSP1+ cells in mice. To confirm that overexpression of IL-15 diminishes pulmonary fibrosis, we generated CC10-rtTA-tetO7-IL-15 transgenic mice and challenged them with Aspergillus antigen. Aspergillus antigen-challenged, doxycycline (DOX)-treated CC10-IL-15 transgenic mice exhibited decreased collagen accumulation, profibrotic cytokine (IL-13 and TGF-β1) expression, and α-SMA+ and FSP1+ cells compared with IL-15-overexpressing mice not treated with DOX. Additionally, to establish that the antifibrotic effect of IL-15 is not limited to allergen-induced fibrosis, we showed that rIL-15 or IL-15 agonist treatment restricted pulmonary fibrosis even in CC10-IL-13 and CC10-TGF-α mice. Mechanistically, we show that T-helper cell type 17 suppressor IL-15-responsive RORγ+ T regulatory cells are induced in DOX-treated, allergen-challenged IL-15-overexpressing mice, which may be a novel pathway for restricting progression of pulmonary fibrosis. Taken together, our data establishes antifibrotic activity of IL-15 that might be a novel therapeutic molecule to combat the development of pulmonary fibrosis | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a IL-13 | |
650 | 4 | |a TGF-β | |
650 | 4 | |a allergen | |
650 | 4 | |a fibrosis | |
650 | 4 | |a lung | |
650 | 7 | |a ALT-803 |2 NLM | |
650 | 7 | |a Allergens |2 NLM | |
650 | 7 | |a Interleukin-13 |2 NLM | |
650 | 7 | |a Interleukin-15 |2 NLM | |
650 | 7 | |a Nuclear Receptor Subfamily 1, Group F, Member 3 |2 NLM | |
650 | 7 | |a Proteins |2 NLM | |
650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
650 | 7 | |a Recombinant Proteins |2 NLM | |
650 | 7 | |a Rorc protein, mouse |2 NLM | |
650 | 7 | |a Transforming Growth Factor alpha |2 NLM | |
650 | 7 | |a Collagen |2 NLM | |
650 | 7 | |a 9007-34-5 |2 NLM | |
650 | 7 | |a Doxycycline |2 NLM | |
650 | 7 | |a N12000U13O |2 NLM | |
700 | 1 | |a Niranjan, Rituraj |e verfasserin |4 aut | |
700 | 1 | |a Manohar, Murli |e verfasserin |4 aut | |
700 | 1 | |a Verma, Alok K |e verfasserin |4 aut | |
700 | 1 | |a Kandikattu, Hemanth K |e verfasserin |4 aut | |
700 | 1 | |a Lasky, Joseph A |e verfasserin |4 aut | |
700 | 1 | |a Mishra, Anil |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t American journal of respiratory cell and molecular biology |d 1989 |g 61(2019), 1 vom: 01. Juli, Seite 97-109 |w (DE-627)NLM012606170 |x 1535-4989 |7 nnns |
773 | 1 | 8 | |g volume:61 |g year:2019 |g number:1 |g day:01 |g month:07 |g pages:97-109 |
856 | 4 | 0 | |u http://dx.doi.org/10.1165/rcmb.2018-0254OC |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 61 |j 2019 |e 1 |b 01 |c 07 |h 97-109 |